We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+21.05%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$340M
AUM Growth
-$154M
Cap. Flow
-$164M
Cap. Flow %
-48.19%
Top 10 Hldgs %
53.86%
Holding
71
New
18
Increased
9
Reduced
13
Closed
25

Top Buys

1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$20.8M
2
BLUE
bluebird bio
BLUE
+$18.5M
3
PTCT icon
PTC Therapeutics
PTCT
+$14.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$11M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$8.97M

Top Sells

1
ECYT
Endocyte, Inc. Common Stock
ECYT
+$20.2M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$17.5M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$16.7M
4
VTRS icon
Viatris
VTRS
+$14.4M
5
IMMU
Immunomedics Inc
IMMU
+$12.1M

Sector Composition

1 Healthcare 84.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$29.6M 8.71%
1,250,000
-600,000
-32% -$12.1M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$24.6M 7.25%
500,000
+237,500
+90% +$8.97M
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.82B
$23.1M 6.81%
175,000
-60,000
-26% -$5.66M
PTCT icon
4
PTC Therapeutics
PTCT
$6.52B
$22.8M 6.7%
675,000
+475,000
+238% +$14.8M
ALNY icon
5
Alnylam Pharmaceuticals
ALNY
$35.7B
$20.7M 6.09%
+210,000
New +$20.8M
BLUE
6
DELISTED
bluebird bio
BLUE
$16.5M 4.85%
+8,106
New +$18.5M
ARGX icon
7
argenx
ARGX
$53.8B
$12.4M 3.66%
150,000
– –
ASND icon
8
Ascendis Pharma A/S
ASND
$17.1B
$11.6M 3.43%
175,000
+35,000
+25% +$2.3M
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
$10.9M 3.22%
+242,000
New +$11M
MRSN
10
DELISTED
Mersana Therapeutics
MRSN
$10.7M 3.15%
24,000
+12,870
+116% +$5.65M
ARWR icon
11
Arrowhead Research
ARWR
$10.5B
$9.52M 2.8%
700,000
-100,000
-13% -$935K
ASMB icon
12
Assembly Biosciences
ASMB
$531M
$9.21M 2.71%
19,583
+7,083
+57% +$3.75M
EXEL icon
13
Exelixis
EXEL
$14.1B
$8.61M 2.53%
+400,000
New +$8.27M
ACAD icon
14
Acadia Pharmaceuticals
ACAD
$4.38B
$8.17M 2.4%
535,000
+135,000
+34% +$2.41M
DRNA
15
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$8.09M 2.38%
660,000
-290,000
-31% -$3.64M
ADMS
16
DELISTED
Adamas Pharmaceuticals
ADMS
$7.62M 2.24%
295,000
-30,000
-9% -$831K
KDMN
17
DELISTED
Kadmon Holdings, Inc.
KDMN
$7.58M 2.23%
1,900,000
+300,000
+19% +$1.17M
ECYT
18
DELISTED
Endocyte, Inc. Common Stock
ECYT
$6.9M 2.03%
500,000
-1,700,000
-77% -$20.2M
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$376M
$6.87M 2.02%
350,000
-500,000
-59% -$9.46M
MDGL icon
20
Madrigal Pharmaceuticals
MDGL
$12.8B
$6.57M 1.93%
+23,500
New +$4.13M
TECX
21
Tectonic Therapeutic
TECX
$615M
$6.57M 1.93%
+19,167
New +$6.91M
CBIO
22
Crescent Biopharma
CBIO
$407M
$6.45M 1.9%
4,000
+1,500
+60% +$2.58M
VRAY
23
DELISTED
ViewRay, Inc.
VRAY
$6.23M 1.83%
900,000
– –
OBSV
24
DELISTED
ObsEva SA Ordinary Shares
OBSV
$6.06M 1.78%
400,000
– –
TCDA
25
DELISTED
Tricida, Inc. Common Stock
TCDA
$5.56M 1.64%
+186,019
New +$5.2M
1
2 3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Ghost Tree Capital held 71 positions worth $340M, down 31% from $494M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Ghost Tree Capital withdrew a net $164M in Q2 2018, closing 25 positions and reducing 13 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $17.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 63% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Alnylam Pharmaceuticals worth $20.7M.

  • Ghost Tree Capital's largest Q2 2018 buy was Alnylam Pharmaceuticals: 210,000 shares worth $20.7M.
  • Ghost Tree Capital added most to PTC Therapeutics in Q2 2018, an estimated $14.8M increase.
  • Ghost Tree Capital's biggest Q2 2018 reduction was Endocyte, Inc. Common Stock, cutting an estimated $20.2M.
  • Ghost Tree Capital fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2018, selling an estimated $17.5M.
  • Ghost Tree Capital's ten largest holdings make up 54% of its $340M portfolio in Q2 2018.
  • Ghost Tree Capital opened 18 new positions and closed 25 in Q2 2018.
  • Ghost Tree Capital's portfolio value fell 31% quarter-over-quarter to $340M.

Based on Ghost Tree Capital's 13F filing for Q2 2018, filed 14 Aug 2018.